John Rakow - Jun 8, 2022 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role: SVP, Genl Counsel, Acting CFO
Signature: John Rakow, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol: ADVM
Transactions as of: Jun 8, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/10/2022, 04:39 PM
Previous filing: Jun 10, 2022
Next filing: Sep 16, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADVM	Stock Option (Right to Buy)	Award	$0	+250K		$0.00	250K	Jun 8, 2022	Common Stock	250K	$1.09	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of June 3, 2022, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of June 3, 2022, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

Content

Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of June 3, 2022, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of June 3, 2022, subject to the Reporting Person's continued service with the Issuer on each such vesting date.